Five Prime Therapeutics, Inc.

Bristol-myers Squibb Compnay

Kevin Hestir

Lewis T Williams

Ernestine A Lee

Stephen Kohl Doberstein

Elizabeth Bosch

Ge Wu

Brian Wong

Katherine E Lewis

Justin Wong

David Bellovin

Emma Masteller

Julie Hambleton

Robert Sikorski

Diane Hollenbaugh

Hongbing Zhang

Minmin Qin

Ali Sadra

Justin G P Wong

Shannon Marshall

Li Long

Thomas Harding

Haishan Lin

Cindy Leo

Aileen Zhou

Servando Palencia

Keting Chu

Amy L Tsui Collins

Dirk Behrens

Robert Forgan Halenbeck

Min Mei Huang

Thomas Linnemann

Jeffrey T Finer

Kalyani Penta

Janine Powers

Penny E Phillips

Srinivas Kothakota

Yan Wang

Michael Carleton

Serena Kimi Perna

Ke Xu

Dimple Pandya

Justin G Wong

Steven Doberstein

Thomas Five Prime Therapeutics Inc Linnemann

Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.

Methods of treating lung cancer

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Methods of treating disease with FGFR1 fusion proteins

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

Disclosed is a newly identified secreted molecule, identified herein as 'monocyte, granulocyte, and dendritic cell colony stimulating factor' (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Compositions and methods of use for MGD-CSF in disease treatment

This invention relates to the polynucleotides and the encoded polypeptides, including novel sequences, of human or non-human primate genes that are amplified in breast and/or other tumor tissues melanoma, as compared to the corresponding normal tissue. The invention also relates to modulators of such polynucleotides and polypeptides, for example, antibodies, that specifically bind to and/or interfere with the activity of this polypeptide, polynucleotide, its fragments, variants, and antagonists. The invention further relates to compositions containing such a polypeptide, polynucleotide, or modulators thereof and uses of such compositions in methods of treating or preventing cancer, by detecting this polynucleotide, polypeptide, or antibodies thereto in patient samples. The invention also provides diagnostic tests for breast cancer and melanoma, by identifying polypeptides and polynucleotides encoded by the cDNA sequence of the invention that correlate with those disorders.

Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma

The invention provides pharmaceutical polypeptide compositions that promote proteoglycan synthesis, and promote the activity of chondrocyte cells, thereby treating arthritis. Methods of providing these compositions to treat arthritis are also provided.

Compositions for treating arthritis comprising HG1023575 polypeptide

Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.

Antibodies to stromal cell-derived factor-1 polypeptides

Growing community of inventors

Kensington, CA, United States of America

Kevin Hestir